参考文献/References:
[1].Assali M,Buda KG,Megaly M,et al. Update on chronic total occlusion percutaneous coronary intervention[J]. Prog Cardiovasc Dis,2021,69:27-34.
[2].Brener SJ, Cunn GJ, Desai PH, et al. A novel risk score to predict one-year mortality in patients undergoing complex high-risk indicated percutaneous coronary intervention (CHIP-PCI)[J]. J Invasive Cardiol,2021,33(4):253-258.
[3].Chieffo A,Dudek D,Hassager C,et al. Joint EAPCI/ACVC expert consensus document on percutaneous ventricular assist devices[J]. Eur Heart J Acute Cardiovasc Care,2021,10(5): 570-583.
[4].中国医师协会心力衰竭专业委员会,国家心血管病专家委员会心力衰竭专业委员会,中华心力衰竭和心肌病杂志编辑委员会. 经皮机械循环辅助临床应用及管理中国专家共识[J]. 中华心力衰竭和心肌病杂志,2020,4(3):145-158.
[5].Kirtane AJ,Doshi D,Leon MB,et al. Treatment of higher-risk patients with an indication for revascularization:evolution within the field of contemporary percutaneous coronary intervention[J]. Circulation,2016,134(5):422-431.
[6].Wilkinson SE,Berkompas DC,Fanning JS,et al. Supporting high-risk percutaneous coronary interventions with mechanical devices[J]. JACC Case Rep,2020,2(5):702-704.
[7].Thiele H,Zeymer U,Neumann FJ,et al. Intraaortic balloon support for myocardial infarction with cardiogenic shock[J]. N Engl J Med,2012,367(14):1287-1296.
[8].Thiele H,Zeymer U,Neumann FJ,et al. Intra-aortic balloon counterpulsation in acute myocardial infarction complicated by cardiogenic shock(IABP-SHOCKⅡ):final 12 month results of a randomised,open-label trial[J]. Lancet,2013,382(9905):1638-1645.
[9].Thiele H,Zeymer U,Thelemann N,et al. Intraaortic balloon pump in cardiogenic shock complicating acute myocardial infarction:long-term 6-year outcome of the randomized IABP-SHOCKⅡtrial[J]. Circulation,2019,139(3):395-403.
[10].Ibanez B,James S,Agewall S,et al. 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation:the task force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology(ESC)[J]. Eur Heart J,2018,39(2):119-177.
[11].O’Gara PT,Kushner FG,Ascheim DD,et al. 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction:executive summary:a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines[J]. Circulation,2013,127(4):529-555.
[12].Khalid N,Zhang C,Shea C,et al. Unprotected left main percutaneous coronary intervention with or without hemodynamic support[J]. Am J Cardiol,2021,154(2):29-32.
[13].周迟,蒋建刚. 急性心肌梗死合并室间隔穿孔患者行主动脉内球囊反搏的疗效[J]. 中国心血管杂志,2021,26(2):4.
[14].郑道阔,葛振伟,朱喜亮,等. 预防性置入主动脉内球囊反搏应用于高危冠心病行冠状动脉旁路移植术患者的临床疗效分析[J]. 中国心血管病研究,2021,19(3):5.
[15].Burzotta F,Trani C,Doshi SN,et al. Impella ventricular support in clinical practice:collaborative viewpoint from a European expert user group[J]. Int J Cardiol,2015,201:684-691.
[16].Iannaccone M,Albani S,Giannini F,et al. Short term outcomes of Impella in cardiogenic shock:a review and meta-analysis of observational studies[J]. Int J Cardiol,2021,324:44-51.
[17].Henriques JP,Remmelink M,Baan J Jr,et al. Safety and feasibility of elective high-risk percutaneous coronary intervention procedures with left ventricular support of the Impella Recover LP 2.5[J]. Am J Cardiol,2006,97(7):990-992.
[18].Dixon SR,Henriques JP,Mauri L,et al. A prospective feasibility trial investigating the use of the Impella 2.5 system in patients undergoing high-risk percutaneous coronary intervention (The PROTECTⅠTrial):initial U.S. experience[J]. JACC Cardiovasc Interv,2009,2(2):91-96.
[19].Sjauw KD,Konorza T,Erbel R,et al. Supported high-risk percutaneous coronary intervention with the Impella 2.5 device the Europella registry[J]. J Am Coll Cardiol,2009,54(25):2430-2434.
[20].Burzotta F,Paloscia L,Trani C,et al. Feasibility and long-term safety of elective Impella-assisted high-risk percutaneous coronary intervention:a pilot two-centre study[J]. J Cardiovasc Med(Hagerstown),2008,9(10):1004-1010.
[21].Maini B,Naidu SS,Mulukutla S,et al. Real-world use of the Impella 2.5 circulatory support system in complex high-risk percutaneous coronary intervention:the USpella Registry[J]. Catheter Cardiovasc Interv,2012,80(5):717-725.
[22].O’Neill WW,Kleiman NS,Moses J,et al. A prospective, randomized clinical trial of hemodynamic support with Impella 2.5 versus intra-aortic balloon pump in patients undergoing high-risk percutaneous coronary intervention:the PROTECTⅡstudy[J]. Circulation,2012,126(14):1717-1727.
[23].Basir MB,Kapur NK,Patel K,et al. Improved outcomes associated with the use of shock protocols:updates from the national cardiogenic shock initiative[J]. Catheter Cardiovasc Interv,2019,93(7):1173-1183.
[24].Ameloot K,B Bastos M,Daemen J,et al. New-generation mechanical circulatory support during high-risk PCI:a cross-sectional analysis[J]. EuroIntervention,2019,15(5):427-433.
[25].Azzalini L,Johal GS,Baber U,et al. Outcomes of Impella-supported high-risk nonemergent percutaneous coronary intervention in a large single-center registry[J]. Catheter Cardiovasc Interv,2021,97(1):E26-E33.
[26].Vranckx P,Schultz CJ,Valgimigli M,et al. Assisted circulation using the TandemHeart during very high-risk PCI of the unprotected left main coronary artery in patients declined for CABG[J]. Catheter Cardiovasc Interv,2009,74(2):302-310.
[27].Dhruva SS,Ross JS,Mortazavi BJ,et al. Use of mechanical circulatory support devices among patients with acute myocardial infarction complicated by cardiogenic shock[J]. JAMA Netw Open,2021,4(2):e2037748.
[28].Alli OO,Singh IM,Holmes DR,et al. Percutaneous left ventricular assist device with TandemHeart for high-risk percutaneous coronary intervention:the Mayo Clinic experience[J]. Catheter Cardiovasc Interv,2012,80(5):728-734.
[29].Gro?ekettler L,Schmack B,Katus HA,et al. Case series of high-risk percutaneous coronary intervention with rotational atherectomy under short-term mechanical circulatory support with TandemHeart in the setting of acute myocardial infarction[J]. Eur Heart J Case Rep,2020,4(4):1-6.
[30].Briasoulis A,Telila T,Palla M,et al. Meta-analysis of usefulness of percutaneous left ventricular assist devices for high-risk percutaneous coronary interventions[J]. Am J Cardiol,2016,118(3):369-375.
[31].Ricarte Bratti JP,Cavayas YA,Noly PE,et al. Modalities of left ventricle decompression during VA-ECMO therapy[J]. Membranes(Basel),2021,11(3):209.
[32].Kowalewski M,Malvindi PG,Zieliński K,et al. Left ventricle unloading with veno-arterial extracorporeal membrane oxygenation for cardiogenic shock. Systematic review and meta-analysis[J]. J Clin Med,2020,9(4):1039.
[33].Amancherla K,Menachem JN,Shah AS,et al. Limited balloon atrial septostomy for left ventricular unloading in peripheral extracorporeal membrane oxygenation[J]. J Card Fail,2021,27(4):501-504.
[34].Unoki T,Kametani M,Matsuura J,et al. Percutaneous coronary intervention on combined VA-ECMO and IMPELLA(ECPELLA) support may reduce myocardial damage in cardiogenic shock patients with STEMI who required mechanical circulatory support[J]. Eur Heart J,2021,10(suppl_1):1534.
[35].Cheng R,Hachamovitch R,Kittleson M,et al. Complications of extracorporeal membrane oxygenation for treatment of cardiogenic shock and cardiac arrest:a meta-analysis of 1,866 adult patients[J]. Ann Thorac Surg,2014,97(2):610-616.
[36].Tomasello SD,Boukhris M,Ganyukov V,et al. Outcome of extracorporeal membrane oxygenation support for complex high-risk elective percutaneous coronary interventions:a single-center experience[J]. Heart Lung,2015,44(4):309-313.
[37].Shaukat A,Hryniewicz-Czeneszew K,Sun B,et al. Outcomes of extracorporeal membrane oxygenation support for complex high-risk elective percutaneous coronary interventions:a single-center experience and review of the literature[J]. J Invasive Cardiol,2018,30(12): 456-460.
[38].Banning AS,Adriaenssens T,Berry C,et al. Veno-arterial extracorporeal membrane oxygenation(ECMO) in patients with cardiogenic shock:rationale and design of the randomised,multicentre, open-label EURO SHOCK trial[J]. EuroIntervention,2021,16(15):e1227-e1236.
[39].Atkinson TM,Ohman EM,O’Neill WW,et al. A practical approach to mechanical circulatory support in patients undergoing percutaneous coronary intervention:an interventional perspective[J]. JACC Cardiovasc Interv,2016,9(9):871-883.
[40].Curtis JP,Rathore SS,Wang Y,et al. Use and effectiveness of intra-aortic balloon pumps among patients undergoing high risk percutaneous coronary intervention:insights from the National Cardiovascular Data Registry[J]. Circ Cardiovasc Qual Outcomes,2012,5(1):21-30.
[41].Randhawa VK,Hoffman K,Bock A,et al. Impella RP as a bridge to cardiac transplant for refractory late right ventricular failure in setting of left ventricular assist device[J]. ESC Heart Fail,2020,7(4):1972-1975.
[42].Kapur NK,Esposito ML,Whitehead E. AortixTM:a novel intra-aortic entrainment pump[J]. Future Cardiol,2021,17(2):283-291.
相似文献/References:
[1]韩培天 魏晓岩 杜彬彬 张津宁 王文州 郭艳娇 张克成 李春彦 李文慧.心肌缺血时间对STEMI患者急诊PCI术后早期左室舒张功能的影响及相关因素分析[J].心血管病学进展,2020,(6):660.[doi:10.16806/j.cnki.issn.1004-3934.2020.06.024]
HAN Pei-tian,WEI Xiaoyan,DU Binbin,et al.Effect of Myocardial Ischemia Duration on Early Left Ventricular Diastolic Function in STEMI Patients After Emergency PCI and Analysis of Related Factors[J].Advances in Cardiovascular Diseases,2020,(5):660.[doi:10.16806/j.cnki.issn.1004-3934.2020.06.024]
[2]贺彩红 荣晶晶 潘宏伟.定量血流分数在急性心肌梗死中的应用进展[J].心血管病学进展,2021,(4):347.[doi:10.16806/j.cnki.issn.1004-3934.2021.04.014]
HE Caihong,RONG Jingjing,PAN Hongwei.Progress in the Application of Quantitative Flow Ratio in Acute Myocardial Infarction[J].Advances in Cardiovascular Diseases,2021,(5):347.[doi:10.16806/j.cnki.issn.1004-3934.2021.04.014]
[3]陈佳仑 李树仁.不同策略血栓抽吸对于急性ST段抬高心肌梗死患者的研究进展[J].心血管病学进展,2021,(7):593.[doi:10.16806/j.cnki.issn.1004-3934.2021.07.005]
CHEN Jialun,LI Shuren.Different Strategies of Thrombus Aspiration in Patients with Acute ST Elevation Myocardial Infarction[J].Advances in Cardiovascular Diseases,2021,(5):593.[doi:10.16806/j.cnki.issn.1004-3934.2021.07.005]
[4]梁晨笛 秦纲.经皮冠状动脉介入诊疗中穿刺路径研究进展[J].心血管病学进展,2022,(3):232.[doi:10.16806/j.cnki.issn.1004-3934.2022.03.000]
LIANG Chendi,QIN Gang.Puncture Routes in Percutaneous Coronary Intervention[J].Advances in Cardiovascular Diseases,2022,(5):232.[doi:10.16806/j.cnki.issn.1004-3934.2022.03.000]
[5]马兴鸿 汪蕾 方纬.核素心肌显像在冠状动脉慢性完全闭塞临床诊疗中的应用价值[J].心血管病学进展,2022,(4):313.[doi:10.16806/j.cnki.issn.1004-3934.2022.04.007]
MA Xinghong,WANG Lei,FANG Wei.Application Value of Radionuclide Myocardial Imaging In the Clinical Diagnosis And Treatment of Coronary Chronic Total Occlusion[J].Advances in Cardiovascular Diseases,2022,(5):313.[doi:10.16806/j.cnki.issn.1004-3934.2022.04.007]
[6]张爽 吴娜琼.腔内影像学在冠状动脉支架内再狭窄诊治应用中的研究进展[J].心血管病学进展,2022,(5):389.[doi:10.16806/j.cnki.issn.1004-3934.2022.05.002]
ZHANG Shuang,WU Na qiong.Application of Intravascular Imaging in Diagnosis and Treatment of Coronary In-Stent Restenosis[J].Advances in Cardiovascular Diseases,2022,(5):389.[doi:10.16806/j.cnki.issn.1004-3934.2022.05.002]
[7]刘文 魏芳晶.药物涂层球囊在真性分叉病变中的研究进展[J].心血管病学进展,2022,(6):511.[doi:10.16806/j.cnki.issn.1004-3934.2022.06.008]
LIU WenWEI Fangjing.Study of Drug-Coated?Balloon in?rue Coronary Bifurcation Lesions[J].Advances in Cardiovascular Diseases,2022,(5):511.[doi:10.16806/j.cnki.issn.1004-3934.2022.06.008]
[8]宋艳华 来春林 杨五小.急性 ST段抬高型心肌梗死患者微血管功能障碍的研究进展[J].心血管病学进展,2022,(6):530.[doi:10.16806/j.cnki.issn.1004-3934.2022.06.013]
SONG Yanhua,LAI Chunlin,YANG Wuxiao.Microvascular Dysfunction in Patients with Acute ST-Segment?levation Myocardial Infarction[J].Advances in Cardiovascular Diseases,2022,(5):530.[doi:10.16806/j.cnki.issn.1004-3934.2022.06.013]
[9]纪欣强 王凡.肥胖悖论与经皮冠状动脉介入治疗预后相关性的研究进展[J].心血管病学进展,2022,(7):615.[doi:10.16806/j.cnki.issn.1004-3934.2022.07.000]
JI XinqiangWANG Fan.Correlation Between Obesity Paradox and Prognosis of Percutaneous Coronary Intervention[J].Advances in Cardiovascular Diseases,2022,(5):615.[doi:10.16806/j.cnki.issn.1004-3934.2022.07.000]
[10]王兰 叶玉兰 宁明安 张迪 尚粉青.血清PCSK9水平与PCI后冠状动脉病变再进展的关系研究[J].心血管病学进展,2022,(7):667.[doi:10.16806/j.cnki.issn.1004-3934.2022.07.000]
WANG Lan,YE Yulan,NING Mingan,et al.Correlation Analysis Between Serum PCSK9 Level and Coronary Artery Pathological ?Progression After PCI[J].Advances in Cardiovascular Diseases,2022,(5):667.[doi:10.16806/j.cnki.issn.1004-3934.2022.07.000]